Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254535 | 1.00 | CA1 (0.65) | CA1ALDH1A1MAPTCYP1A2MEN1 | |
| SCHEMBL30960322 | 1.00 | CA1 (0.65) | CA1ALDH1A1MAPTCYP1A2MEN1 | |
| SCHEMBL13254536 | 0.83 | CA1 (0.46) | CA1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3486566 | 0.83 | CA1 (0.46) | CA1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14292075 | 0.81 | CA1 (0.61) | CA1ALDH1A1MAPTCYP1A2MEN1 | |
| SCHEMBL30735990 | 0.81 | CA1 (0.61) | CA1ALDH1A1MAPTCYP1A2MEN1 | |
| SCHEMBL29065866 | 0.79 | CA1 (1.00) | CA1ALDH1A1MAPTCYP1A2L3MBTL1 | |
| SCHEMBL16268173 | 0.79 | ALDH1A1 (0.46) | CA1ALDH1A1MAPTCYP1A2MEN1 | |
| SCHEMBL3486328 | 0.77 | CA1 (0.51) | CA1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL13254537 | 0.77 | CA1 (0.51) | CA1ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113559926-A | Asymmetric Aldol reaction catalyst and preparation method and application thereof | 北方民族大学 | 2021-10-29 | — | — | CN | disclosed |
| CN-107497485-B | Water-phase asymmetric Aldol reaction catalyst and preparation method and application thereof | 石家庄学院 | 2020-04-17 | — | — | CN | disclosed |
| CN-110627647-A | High diastereoselectivity 2- (hydroxy (phenyl) methyl) cyclohexanone derivative and preparation method thereof | 广东工业大学 | 2019-12-31 | — | — | CN | disclosed |
| US-8399684-B2 | Sulfonamide-based organocatalysts and method for their use | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100184986-A1 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | The State of Oregon acting by and through the State Board of Higher Education on behalf of Orego | 2010-07-22 | — | — | US | disclosed |
| WO-2009039181-A2 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | STATE OF OREGON ACTING BY & THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OR. STATE UNIV. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184986-A1 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | ALDH7A1, SULT1A1, SULT2A1 | CA1 1253/4885ALDH1A1 12/4885MAPT 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.